Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-β, and MAPK signaling pathways during breast tumor progression.
Amirhosein MaharatiMeysam MoghbeliPublished in: Journal of translational medicine (2023)
Breast cancer (BC) as one of the most common causes of human deaths among women, is always considered one of the global health challenges. Despite various advances in diagnostic and therapeutic methods, a significant percentage of BC patients have a poor prognosis due to the lack of therapeutic response. Therefore, investigating the molecular mechanisms involved in BC progression can improve the therapeutic and diagnostic strategies in these patients. Cytokine and growth factor-dependent signaling pathways play a key role during BC progression. In addition to cytokines and growth factors, long non-coding RNAs (lncRNAs) have also important roles in regulation of such signaling pathways. Therefore, in the present review we discussed the role of lncRNAs in regulation of PI3K/AKT, MAPK, and TGF-β signaling pathways in breast tumor cells. It has been shown that lncRNAs mainly have an oncogenic role through the promotion of these signaling pathways in BC. This review can be an effective step in introducing the lncRNAs inhibition as a probable therapeutic strategy to reduce tumor growth by suppression of PI3K/AKT, MAPK, and TGF-β signaling pathways in BC patients. In addition, considering the oncogenic role and increased levels of lncRNAs expressions in majority of the breast tumors, lncRNAs can be also considered as the reliable diagnostic markers in BC patients.
Keyphrases
- pi k akt
- signaling pathway
- poor prognosis
- end stage renal disease
- long non coding rna
- cell proliferation
- chronic kidney disease
- cell cycle arrest
- newly diagnosed
- induced apoptosis
- peritoneal dialysis
- growth factor
- epithelial mesenchymal transition
- prognostic factors
- oxidative stress
- endothelial cells
- public health
- transcription factor
- global health
- network analysis
- pregnant women
- type diabetes
- patient reported outcomes
- insulin resistance
- induced pluripotent stem cells